Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 3
1(25.0%)
Phase 2
1(25.0%)
4Total
N/A(2)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03650816Completed

Cerebrovascular Reactivity in Alzheimer's Disease

Role: collaborator

NCT03435861Phase 2Completed

Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients

Role: collaborator

NCT02164643Phase 3Completed

Longitudinal Study of Brain Amyloid imaGing in MEMENTO

Role: collaborator

NCT01926249Completed

A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders

Role: collaborator

NCT03923569Not ApplicableUnknown

Epileptiform Activity During REM Sleep in Alzheimer's Disease

Role: collaborator

NCT02196116Not ApplicableUnknown

Amyloïd Load in Elderly Population: Effect of Cognitive Reserve

Role: collaborator

All 6 trials loaded